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The ro le of  surgery in  the t reatment  of  pat ients wi th a nonseminomatous test i -
cular tumor (NSTT) is described in this thesis on the basis of f ive articlcs. The
study was star ted at  the end of  1977 whcn the chemotherapeut ic  c isp lat in
became avai lable at  the Groningen Univers i ty  Hospi ta l .
The introducticln (Clrapter I) discusses two distinct groups of germ cell tumors
of  the test is :  seminomatous e ind nonseminomatous tumors.  Al l  pat ients d iscussed
in this thesis were treated for a NSTT. The histological classification of testicular
tumors is briefly discussed, using the nomenclature of the World Health Organi-
zation. It is also pointed out that some subgroups of testicular tumors produce
specific tumor markers dc'monstrable in the patient's serum. The clinical staging
of  NSTT is  a lso out l ined.  wi th specia l  reterence to the Peckham staging r rou ' in  usc
and that of Skinner and Scardino which was usecl in the past. Surgery can bc of
great  importance both in  the d iagnosis and in the t reatment  of  test icu lar  tumors.
Surgery is  d iagnost ic  i f  the tumor s ize is  determined in an exploratory operat ion.
in  which t issue may a lso be removed fc l r  h is to logic  exanr inat ion.  Surgery is  thera-
pcut ic  i f  i t  compr ises tumor resect i t rn.
A fairly detailed acc()unt is presented of the past and current methods of trcating
these pat ients.
Finally, four questions are formulatecl which promted this study. The answers tcr
these quest ions are d iscussed in the subsequent  f ive chapters.
Chzrpter II discusses 54 patients with NSTT in clinical Stage I, followed in an ex-
pectant strategy during the period 1982-1985. This expectant strategy or wait-
and-see policy means that, if no metastases are demonstrated after hemiorchidec-
tomy,  pat ients are merely  submit ted t ( )  very f requent  check-ups dur ing subse-
quent  vears.  This wai t -and-see pol icy has the advantage over  the pol icy focused
on retroperitoneal ymph node dissection (RLND), as acceptecl up to 1982, that
some 80o/o f the patients can be saved an operation which carries a degree of mor-
bidity. the important complication being retrograde ejaculation clisorders.
Since diagnostic radiologv was init iallv considered not sufficientl,v reliable in
screening for retroperitoneal metast2rses, an exploratory laparotomy was pertbrm-
ed to complete the dissemination study in 1982 and 19U3. Once it was found that
this intervention supplied virtually no additional information, it was performed
only if strictly indicated from 1981 on.
The recurrence rate with a wait-and-see policy is about tw,ice as high as thzrt with
RLND (207o versus 10%), but these recurrences respond very well to combina-
tion chemotherapy with cisplatin. In order to reduce recurrences an attempt was
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made to identify possible predictive criteria. However, neither the histology of
the testicular tumor nor the serum tunror marker levels were found to be of prog-
nostic value in this study'.
It is concluded that a wait-and-see policy is reliable as long as patients are submit-
ted to f requent  check-ups.  I f  th is  cannot  be ensured,  then RLND remains indi -
cated.
Chapter  I  I I  c l iscusses 2,5 pat ients in  whom retroper i toneal  lvmph node metasta-
ses of a NS'fT were trezrted with combination chemotherapy comprising cisplatin,
v inblast ine and b leomycin (PVB) between 1978 and Apr i l  1983.  In 2 l  cases th is
chemotherapy was preceded by an exploratory laparotomy for definit ive tumor
staging. During chemotherapy one patient died from cligestive tract hemorrhage
resulting from a very large tumor invading the intestinal wall and the aorta. In the
remaining 24 cases the serum tumor markcr levels normalized after chemothera-
py. All these patients underwent a laparotomy at which residual tumor tissuc (if
anv)  was renroved.
Four patients proved to have no denronstrable residual tumor. Of the remaining
20 pat ients,  l3  showed necrosis  and f ibros is  in  the res idual  tumorwhi le  7 had a
mature teratoma. Mal ignant  umor t issue was no longer found.
At the end of the study these 24 patients were all sti l l  alive after an average follow-
up of ,56 months. Two had developed a recurrence for which one patient was sti l l
being treated at completion of this study. The other proved to have developed a
secondary malignancy in a teratoma remnant after 73 months.
On the basis of a comparison of the histology of the primary tumor with that of the
residual tumor, and in view of the tact that radiological f indings on the retroperi-
toneum are not entirely reliable, it is advisable to make the indication for laparoto-
my following chemotherapy at least partly dependent on the histology of the pri-
mary tumor.  i .e .  the presence of  a teratoma component .
Chzrpter lV discusses 53 patients l ikewise given PVB chemotherapy during the
period 1978- 19U3. These patients had lymphogenous metastases below and above
the diaphragm (Stage III) and/or lung metastases (Stage IV). After the remission-
induction chemotherapy 4l showed normalization of the serum tumor marker lev-
els. They were further evaluated and, in the end, exploratory surgery was per-
formed in 35 patients. Malignant tumor tissue was found in the residual tumor in 4
patients, mature teratoma in 16, necrosis and fibrosis in l4 patients, while one pa-
tient no krnger had any lesions. At completion of the study 38 patients (727o ) were
st i l l  a l ive af ter  an average fo l low-up of  65 months.  Six  pat ients ( l0%) had devel -
oped a recurrence, which led to a fataloutcome in two. The therapeutic results are
further discussed on the basis of the histolosv of the residual tumor and the init ial
tumor volume.
It is concluded that the prognosis is poor when the serum tumor marker levels are
sti l l  increased after remission-induction chemotherapy. This is in contrast to the
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situation of patients in whom the presence of malignant tumor is demonstrable
only from the histology of the resected residual tumor. This study clearly showed
that the indication for laparotomy and/or thoracotomy following chemotherapy
should be made partly dependent on the presence of a teratoma component in the
primary tumor. Finally, the init ial tumor volume was found to be of unmistakable
prognostic significance
Chapter V discusses the growing mature teratoma with reference to three case
histories, selected from 86 patients treated during the period 1978-1983 by PVB
chemotherapy in view of a NSTT with metastases.
A growing mature teratoma can be suspected on clinical grounds when in the
course of the follow-up a recurrence is observed in patients with a teratoma com-
ponent in the primary tumor with normal serum tumor marker levels. Such a recur-
rence always dictates surgical exploration because, in addition to a growing
mature teratoma, mal ignant  tumor t issue or  secondary mal ignancy may be in-
volved. En bloc resection of the recurrent tumor is sufficient in the treatment of a
growing mature teratoma.
In the discussion it is pointed out that tumors of this type are histologically benign
but cytogenetically malignant. Other studies have shown that remnants of maturc
tcratoma tissue can develop in the course of t ime to large, usually cystic tumors.
For patients with a teratoma component in the primary tumor this implies the ne-
cessity of trying, after chemotherapy, to resect all residual tumor tissuc in ordcr tcr
prevent subsequent development of a growing mature teratoma.
Chapter VI describes the investigations required for reliable determination of
the condition of the retroperitoneal ymph nodes in patients with a NSTT. This is
done with reference to 32 cases in which the assessments of the abdominal CT
scan and lymphography were compared with the findings at exploratory laparoto-
my. The comparison showed that the absence of metastases can be reliably dem-
onstrated with the CT scan, while lymphography and laparotomy provide but l i tt-
le additional information. The presence of metastases can likewise be reliably
demonstrated with the CT scan. Attempts to determine the tumor stage and tu-
mor volume on the basis of these data, however. are less reliable. Lymphography
supplies hardly any additional information in this respect, but exploratory laparo-
tomy does give much additional information. It is concluded that the CT scan is
sufficient o delineate clinical Stage I . For exact delineation of higher stages an ad-
ditional exploratory laparotomy is required. According to this study there is no
longer an indication for lymphography to search for retroperitoneal ymph node
metastases in patients with a NSTT.
In the general discussion the current strategy is evaluated on the basis of the re-
sults reported in this thesis. Desirable changes in strategy are outl ined in view of
this evaluation. These changes in strategy concern the diagnosis as well as the
treatment of nonseminomatous testicular tumors.
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